Dear members and friends,

It is my pleasure to announce GZOPA's third seminar of 2005 with two outstanding speakers. Don't miss this opportunity to be educated when many infectious disease experts in the world believe that the world stands on the verge of an influenza pandemic.

Sincerely,
Sam Liu
President of GZOPA

Speech Outline:

The last three pandemics, occurring in 1918, 1957 and 1968, totally killed approximately 43 million people worldwide. With the H5N1 avian flu virus spreading from Asia to Europe, many people may ask is an influenza pandemic inevitable or can we contain the outbreak at its beginning and avert a flu pandemic? Come and listen to what the experts will say. With a deep understanding of the virus infection mechanisms, the speakers will also discuss what we may do to minimize the impact of possible catastrophic consequences.

发生在上世纪的三次全球大流感(1918, 1957 及1968)共夺取约4千3百万人的生命。 随着H5N1禽流感病毒在亚洲，欧洲及世界其他地方传播，越来越多的人禁不住地想知道禽流感病毒 引发全球大流感是否无可避免，或许能将大流感控制在初发之时使其无法肆虐人类。 在海外贵州促进会针对禽流感病毒的专题讲座上，罗培志博士及张杰博士将从禽流感病毒转播机制的角度 对以上问题提供专业的见解。同时也会探讨一旦爆发全球大流感时可采取防范措施以减低对人类的危害。

Speaker's Profile:

Peter P. Luo, Ph.D., Cofounder and CTO, Abmaxis, Inc.

Dr. Luo has extensive experience in designing and studying the folding, stability and activity of biopolymers by applying a broad multi-disciplinary approach that combines methods and ideas of experimental and computational biology, chemistry and physics. His current interest focuses on the structure-function relationship of proteins, and antibodies in particular, involved in cancer and other diseases. Prior to founding Abmaxis, Dr Luo was the first scientist to join Xencor, Inc and managed its protein chemistry department. He designed novel, improved variants of key pharmaceutical proteins and demonstrated their efficacies in vitro and in vivo testing. Dr Luo received a postdoctoral fellowship from the Arthritis Foundation in studying protein folding & design with Dr. Robert Baldwin at Stanford University. He received his Ph.D. in physical and bioorganic chemistry from The University of Chicago, a MS degree in chemical physics from The Institute of High Energy Physics of the Chinese Academy of Sciences, and a B.S. degree in chemistry from Peking University.

Jie Zhang, Ph.D., Associate Director of R&D, Corgentech Inc (Nasdaq: CGTK)

Dr. Zhang currently working on the therapeutic target discovery and validation in various diseases. He has extensive experiences in genomic data mining, genome wide data analysis, and in the assay development of genetic testing. Prior to this, he also worked as a contract scientist for Hyseq Inc and Protogen Inc, where he contributed to the novel gene discovery and the development of assay in diagnostic of diseases. Dr. Zhang was a cofounder of GenMetrics Inc, a biopharmaceutical company developed a proprietary platform to discover, characterize, and validate unknown protein pathway. He also founded the Infogene.com, a system biology based genomics and genetics consulting group. Dr. Zhang is the inventor and co-inventor for many patents.
Dr Zhang received a postdoctoral training in studying the human genome with Dr. Richard Myers at Genetics Department of Stanford University. He received his Ph.D. in Neuroscience and Genetics from The University of Utah, a MS degree in Biomedical Science and Ophthalmology from Sun Yat-sen University, and a B.S. degree in Biology from Nanjing University.